drugset / Trial / NCT07045805
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
Phase 2
Not yet recruiting
66 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NaSingle-groupOpen-labelTreatment
Summary
The study aims to evaluate the efficacy and safety of the QL1706 combination with paclitaxel and bevacizumab in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard therapy.
Timeline
- Start
- 2025-07-25
- Primary completion
- 2027-07-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Background | Paclitaxel | Small molecule | 150 mg/m2 | — |